Company Profile for Atara Biotherapeutics, Inc.

April 2, 2020 12:33 UTC

--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The Company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by our state-of-the-art manufacturing facility in Thousand Oaks, California. For additional information about the Company, please visit atarabio.com.

Company:

 

Atara Biotherapeutics, Inc.

     

Headquarters Address:

 

611 Gateway Blvd

   

Suite 900

   

South San Francisco, CA 94080

     

Main Telephone:

 

(650) 278-8930

     

Website:

 

https://www.atarabio.com/

     

Ticker:

 

ATRA (NASDAQ)

     

Type of Organization:

 

Public

     

Industry:

 

Biotechnology

     

Key Executives:

 

CEO: Pascal Touchon

   

CFO: Utpal Koppikar

   

COO: Joe Newell

     

Investor Relations

   

Contact:

 

John Craighead

Phone:

 

650-410-3012

Email:

 

jcraighead@atarabio.com

     

Public Relations

   

Contact:

 

Kerry Beth Daly

Phone:

 

516-982-9328

Email:

 

kdaly@atarabio.com

     

Investor Relations

   

Contact:

 

Susanna Chau

Phone:

 

650-477-8024

Email:

 

schau@atarabio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005244/en/

Source: Atara Biotherapeutics, Inc.

Back to news